Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 1994The Annals of Thoracic SurgeryOpen Access

Thromboembolic risk and late survival after mitral valve replacement with the St. Jude Medical valve

View Full Paper
Ask AI
Bookmark
Share

Key result

Mitral valve replacement with the St. Jude Medical valve was associated with an early (30-day) mortality of 3.5% and a 10-year actuarial survival of 73%.

Population

397 consecutive patients undergoing mitral valve replacement with the St. Jude Medical valve. Associated…

Design

Cohort

Follow-up

mean 6.1 +/- 0.2 years

Authors

OJOlivier JegadenUniversité Claude Bernard Lyon 1AEArmand EkerInternational University of MonacoFDFrançois DelahayeUniversité Claude Bernard Lyon 1

Discussion

Loading...

Member takes

Implication

May guide expectations for mechanical mitral replacement; leaves open comparative effectiveness versus modern valves in randomized data.

Study Design

Type

Cohort (n=397)

Structured PICO

P
Population
397 consecutive patients (mean age 55 years) undergoing mitral valve replacement with the St. Jude Medical valve, followed for a mean of 6.1 years.
E
Exposure
Mitral valve replacement with the St. Jude Medical valve, followed by continuous intravenous heparin starting on the first postoperative day until effective oral anticoagulation (INR 3 to 4.5) was achieved (started on the seventh day).
O
Outcome
Late survival and thromboembolic riskhard clinical

Mitral valve replacement with the St. Jude Medical valve demonstrates acceptable 10-year survival, though patients with advanced preoperative functional class or requiring multiple valve replacements have higher mortality.

Cite This Study

Jegaden et al. (1994) conducted a cohort in Mitral valve disease requiring replacement (n=397). Mitral valve replacement with the St. Jude Medical valve was evaluated on 10-year actuarial survival. Mitral valve replacement with the St. Jude Medical valve was associated with an early (30-day) mortality of 3.5% and a 10-year actuarial survival of 73%.

synapsesocial.com/papers/6a9543d3b1a163ea017698a1https://doi.org/10.1016/0003-4975(94)91669-1
View Full Paper
Ask AI
Bookmark
Share